371 related articles for article (PubMed ID: 14719114)
1. Reduction of in vivo lung metastases by dinuclear ruthenium complexes is coupled to inhibition of in vitro tumour invasion.
Bergamo A; Stocco G; Casarsa C; Cocchietto M; Alessio E; Serli B; Zorzet S; Sava G
Int J Oncol; 2004 Feb; 24(2):373-9. PubMed ID: 14719114
[TBL] [Abstract][Full Text] [Related]
2. Synthesis and chemical-pharmacological characterization of the antimetastatic NAMI-A-type Ru(III) complexes (Hdmtp)[trans-RuCl4(dmso-S)(dmtp)], (Na)[trans-RuCl4(dmso-S)(dmtp)], and [mer-RuCl3(H2O)(dmso-S)(dmtp)] (dmtp = 5,7-dimethyl[1,2,4]triazolo[1,5-a]pyrimidine).
Velders AH; Bergamo A; Alessio E; Zangrando E; Haasnoot JG; Casarsa C; Cocchietto M; Zorzet S; Sava G
J Med Chem; 2004 Feb; 47(5):1110-21. PubMed ID: 14971891
[TBL] [Abstract][Full Text] [Related]
3. Dual Action of NAMI-A in inhibition of solid tumor metastasis: selective targeting of metastatic cells and binding to collagen.
Sava G; Zorzet S; Turrin C; Vita F; Soranzo M; Zabucchi G; Cocchietto M; Bergamo A; DiGiovine S; Pezzoni G; Sartor L; Garbisa S
Clin Cancer Res; 2003 May; 9(5):1898-905. PubMed ID: 12738748
[TBL] [Abstract][Full Text] [Related]
4. Ruthenium-based NAMI-A type complexes with in vivo selective metastasis reduction and in vitro invasion inhibition unrelated to cell cytotoxicity.
Bergamo A; Gava B; Alessio E; Mestroni G; Serli B; Cocchietto M; Zorzet S; Sava G
Int J Oncol; 2002 Dec; 21(6):1331-8. PubMed ID: 12429985
[TBL] [Abstract][Full Text] [Related]
5. Lack of In vitro cytotoxicity, associated to increased G(2)-M cell fraction and inhibition of matrigel invasion, may predict In vivo-selective antimetastasis activity of ruthenium complexes.
Zorzet S; Bergamo A; Cocchietto M; Sorc A; Gava B; Alessio E; Iengo E; Sava G
J Pharmacol Exp Ther; 2000 Dec; 295(3):927-33. PubMed ID: 11082425
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of B16 melanoma metastases with the ruthenium complex imidazolium trans-imidazoledimethylsulfoxide-tetrachlororuthenate and down-regulation of tumor cell invasion.
Gava B; Zorzet S; Spessotto P; Cocchietto M; Sava G
J Pharmacol Exp Ther; 2006 Apr; 317(1):284-91. PubMed ID: 16368900
[TBL] [Abstract][Full Text] [Related]
7. Distinct effects of dinuclear ruthenium(III) complexes on cell proliferation and on cell cycle regulation in human and murine tumor cell lines.
Bergamo A; Stocco G; Gava B; Cocchietto M; Alessio E; Serli B; Iengo E; Sava G
J Pharmacol Exp Ther; 2003 May; 305(2):725-32. PubMed ID: 12606643
[TBL] [Abstract][Full Text] [Related]
8. TGFbeta1 regulation and collagen-release-independent connective tissue re-modelling by the ruthenium complex NAMI-A in solid tumours.
Casarsa C; Mischis MT; Sava G
J Inorg Biochem; 2004 Oct; 98(10):1648-54. PubMed ID: 15458828
[TBL] [Abstract][Full Text] [Related]
9. Fate of the antimetastatic ruthenium complex ImH [trans-RuCl4(DMSO)Im] after acute i.v. treatment in mice.
Cocchietto M; Salerno G; Alessio E; Mestroni G; Sava G
Anticancer Res; 2000; 20(1A):197-202. PubMed ID: 10769655
[TBL] [Abstract][Full Text] [Related]
10. Antimetastatic properties and DNA interactions of the novel class of dimeric Ru(III) compounds Na2[[trans-RuCl4(Me2SO)]2(mu-L)] (L = ditopic, non-chelating aromatic N-ligand). A preliminary investigation.
Alessio E; Iengo E; Zorzet S; Bergamo A; Coluccia M; Boccarelli A; Sava G
J Inorg Biochem; 2000 Apr; 79(1-4):173-7. PubMed ID: 10830863
[TBL] [Abstract][Full Text] [Related]
11. In vitro cell cycle arrest, in vivo action on solid metastasizing tumors, and host toxicity of the antimetastatic drug NAMI-A and cisplatin.
Bergamo A; Gagliardi R; Scarcia V; Furlani A; Alessio E; Mestroni G; Sava G
J Pharmacol Exp Ther; 1999 Apr; 289(1):559-64. PubMed ID: 10087050
[TBL] [Abstract][Full Text] [Related]
12. Synthesis, structural characterization, solution chemistry, and preliminary biological studies of the ruthenium(III) complexes [TzH][trans-RuCl4(Tz)2] and [TzH][trans-RuCl4(DMSO)(Tz)].(DMSO), the thiazole analogues of antitumor ICR and NAMI-A.
Mura P; Camalli M; Messori L; Piccioli F; Zanello P; Corsini M
Inorg Chem; 2004 Jun; 43(13):3863-70. PubMed ID: 15206867
[TBL] [Abstract][Full Text] [Related]
13. In vivo tumour and metastasis reduction and in vitro effects on invasion assays of the ruthenium RM175 and osmium AFAP51 organometallics in the mammary cancer model.
Bergamo A; Masi A; Peacock AF; Habtemariam A; Sadler PJ; Sava G
J Inorg Biochem; 2010 Jan; 104(1):79-86. PubMed ID: 19906432
[TBL] [Abstract][Full Text] [Related]
14. The role of cisplatin and NAMI-A plasma-protein interactions in relation to combination therapy.
Khalaila I; Bergamo A; Bussy F; Sava G; Dyson PJ
Int J Oncol; 2006 Jul; 29(1):261-8. PubMed ID: 16773208
[TBL] [Abstract][Full Text] [Related]
15. Down-regulation of tumour gelatinase/inhibitor balance and preservation of tumour endothelium by an anti-metastatic ruthenium complex.
Sava G; Capozzi I; Bergamo A; Gagliardi R; Cocchietto M; Masiero L; Onisto M; Alessio E; Mestroni G; Garbisa S
Int J Cancer; 1996 Sep; 68(1):60-6. PubMed ID: 8895542
[TBL] [Abstract][Full Text] [Related]
16. Replacement of chlorides with dicarboxylate ligands in anticancer active Ru(II)-DMSO compounds: a new strategy that might lead to improved activity.
Bratsos I; Serli B; Zangrando E; Katsaros N; Alessio E
Inorg Chem; 2007 Feb; 46(3):975-92. PubMed ID: 17257042
[TBL] [Abstract][Full Text] [Related]
17. Increase of tumour infiltrating lymphocytes in mice treated with antimetastatic doses of NAMI-A.
Magnarin M; Bergamo A; Carotenuto ME; Zorzet S; Sava G
Anticancer Res; 2000; 20(5A):2939-44. PubMed ID: 11062704
[TBL] [Abstract][Full Text] [Related]
18. Effects of some ruthenium chelates on MCa mammary carcinoma and on TLX5 lymphoma in mice.
Bregant F; Pacor S; Ghosh S; Chattopadhyay SK; Sava G
Anticancer Res; 1993; 13(4):1011-7. PubMed ID: 8352519
[TBL] [Abstract][Full Text] [Related]
19. Intratumoral NAMI-A treatment triggers metastasis reduction, which correlates to CD44 regulation and tumor infiltrating lymphocyte recruitment.
Pacor S; Zorzet S; Cocchietto M; Bacac M; Vadori M; Turrin C; Gava B; Castellarin A; Sava G
J Pharmacol Exp Ther; 2004 Aug; 310(2):737-44. PubMed ID: 15075381
[TBL] [Abstract][Full Text] [Related]
20. Ruthenium(III) dimethyl sulfoxide pyridinehydroxamic acid complexes as potential antimetastatic agents: synthesis, characterisation and in vitro pharmacological evaluation.
Griffith D; Cecco S; Zangrando E; Bergamo A; Sava G; Marmion CJ
J Biol Inorg Chem; 2008 May; 13(4):511-20. PubMed ID: 18183430
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]